Trials / Unknown
UnknownNCT02366325
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis
A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety,efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) who are on hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPO-018B |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-02-19
- Last updated
- 2015-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02366325. Inclusion in this directory is not an endorsement.